Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid

Journal of Clinical Gastroenterology

Volumn 44, Issue 5, 2010, Pages 371-373

  Hazzan, Rawi ^a   Tur Kaspa, Ran ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Bezafibrate; Incomplete biochemical response; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; BEZAFIBRATE; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ALKALINE PHOSPHATASE; ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 77951726522     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181c115b3     Document Type: Article

References (23)

1. Lazaridis KN, Talwalker JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol. 2007;41:494-500.
2. Doniach D, Roitt IM, Walker JG, et al. Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol. 1966;1:237-262.
3. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113: 884-890.
4. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology. 1985;89:1084-1091.
5. Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of long-term placebo controlled trial. Gastroenterology. 1993;104:519-526.
6. Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid for treatment of primary biliary cirrhosis. Hepatology. 2005;42:1184-1193.
7. Gong Y, Gluud C. Colchicine for primary liver cirrhosis: a cochrane hepato-biliary group systematic review of randomized clinical trials. Am J Gastroenterol. 2005;100:1876-1885.
8. Fukuo Y, Kitami T, Nomoto T, et al. A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (AL-P and gamma-GTP). Nippon Ika Daigaku Zasshi. 1996;63:424-430.
9. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715-720.
10. Chianale J, Vollrath V, Wielandt AM, et al. Fibrates induce MDR2 gene expression and biliary phospolipid secretion in the mouse. Biochem J. 1996;314:781-786.
11. Miranda S, Vollrath V, Wielandt AM, et al. Overexpression of MDR2 gene by peroisome proliferation in the mouse liver. J Hepatol. 1997;26:1331-1339.
12. Staels B, Koening W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR alfa but not by PPAR gama activators. Nature. 1998;393:790-793.
13. Nishiyoka T, Hyogo H, Numata Y, et al. A nuclear receptormediated choleretic action of fibrates is associated with enhanced membrane fluidity and transporter activity mediating bile acid-independent bile secretion. J Atheroscler Thromb. 2005;12:211-217.
14. Devchand PR, Keller H, Peters JM, et al. The PPAR alphaleukotriene B4 pathway to inflammation control. Nature. 1996;384:39-43.
15. Nakai S, Masaki T, Kurokohchi K, et al. Combination therapy of bezafibrate and ursodeoxycholic acidin primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000;95: 326-327.
16. Nakamuta M, Enjoji M, Kotoh K, et al. Long-term fibrate treatment for PBC. J Gastroenterol. 2005;40:546-547.
17. Ohmoto K, Yoshioka N, Yamamoto S. Long-term effect of bezafibrate on parameters of hepatic fibrosis in primay biliary cirrhosis. J Gastroenterol. 2006;41:502-503.
18. Kanda T, Yokosuka O, Imazeki F, et al. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38:573-578.
19. Kita R, Takamatsu S, Kimura T, et al. Bezafibrate may attenuate biliary damage associate with chronic liver diseases accompanied by high serum biliary enzyme level. J Gastroenterol. 2006;41:686-692.
20. Yano M, Kato H, Morita S, et al. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol. 2002; 97:1075-1077. (Pubitemid 34408290)
21. Kurihara T, Maeda A, Shigemoto M, et al. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological from cases receiving long term monotherapy. Am J Gastroenterol. 2002;97:212-214.
22. Kurihara T, Furukawa M, Tsuchiya M, et al. Effect of bezafibrate in the treatment of primay biliary cirrhosis. Curr Ther Res. 1999;61:83-96.
23. Kurihara T, Niimi A, Maeda A, et al. Bezafibrate in the treatment of primary biliary cirrhosis. Am J Gastroenterol. 2000;95: 2990-2992.